Overview

A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

Status:
RECRUITING
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of SHR-3167 at steady state in subjects with type 2 diabetes.
Phase:
PHASE1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
insulin degludec